Poly(ADP-ribose) polymerases inhibitors (PARPi) that target both the PARP-1 and PARP-2 enzymes (e.g., olaparib, niraparib, rucaparib and talazoparib) have been the first DDR-targeting compounds approved for treatment of some tumours bearing homologous recombination (HR) DNA repair deficiencies [3], acting on the principle of synthetic lethality [4,5]. Here, PARP1 is linked to neoplasm.